{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:30:25Z","timestamp":1791084625379,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaip.2025.07.038","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:00:06Z","timestamp":1754431206000},"page":"2700-2710.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Melek","family":"Cihanbeylerden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazal","family":"Kay\u0131k\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7ise","family":"T\u00fcccar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl Pehlivanlar","family":"Ustao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Damadoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl","family":"Karakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fuat","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.07.038_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.07.038_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.07.038_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1164\/ajrccm\/146.1.76","article-title":"Long-term prognosis of near-fatal asthma: a 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma","volume":"146","author":"Ch","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2025.07.038_bib5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2005.08.035","article-title":"Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma","volume":"116","author":"Mascia","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/000348941112000304","article-title":"Revision rates after endoscopic sinus surgery: a recurrence analysis","volume":"120","author":"Mendelsohn","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2025.07.038_bib7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/all.12260","article-title":"Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs","volume":"68","author":"Kowalski","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.07.038_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12235","article-title":"Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease","volume":"13","author":"Mastalerz","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2025.07.038_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2013.07.004","article-title":"Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis","volume":"133","author":"Bochenek","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.07.038_bib11","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2025.03.006","article-title":"Clinical and mechanistic advancements in aspirin exacerbated respiratory disease","volume":"155","author":"Elahi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib12","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1, 11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jaci.2006.01.046","article-title":"Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation","volume":"117","author":"Fahy","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.07.038_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/alr.22888","volume":"12","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2025.07.038_bib17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/alr.22135","article-title":"Establishing the minimal clinically important difference for the Questionnaire of Olfactory Disorders","volume":"8","author":"Mattos","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2025.07.038_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2307\/2528823","article-title":"A general coefficient of similarity and some of its properties","author":"Gower","year":"1971","journal-title":"Biometrics"},{"key":"10.1016\/j.jaip.2025.07.038_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00357-014-9161-z","article-title":"Ward\u2019s hierarchical agglomerative clustering method: which algorithms implement Ward\u2019s criterion?","volume":"31","author":"Murtagh","year":"2014","journal-title":"J Classification"},{"key":"10.1016\/j.jaip.2025.07.038_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy","volume":"147","author":"Stevens","year":"2021","journal-title":"Asthma & Immunology. J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1080951","article-title":"Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?","volume":"4","author":"Van Broeck","year":"2023","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2025.07.038_bib22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/resp.14578","article-title":"Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics","volume":"28","author":"Langton","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2025.07.038_bib23","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.07.038_bib24","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.07.038_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.07.038_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.07.038_bib27","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.07.038_bib28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1159\/000514262","article-title":"Real-life experience of monoclonal antibody treatments in chronic rhinosinusitis with nasal polyposis","volume":"182","author":"Meier","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti\u2013IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib31","first-page":"37","article-title":"Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti-IL-5 biologics: a real-life study","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib33","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.07.038_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaci.2012.08.002","article-title":"IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization","volume":"131","author":"Chu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"\u015awierczy\u0144ska-Kr\u0119pa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4168\/aair.2018.10.2.121","article-title":"Therapeutic effect of omalizumab in severe asthma: a real-world study in Korea","volume":"10","author":"Lee","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2025.07.038_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.07.038_bib39","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2025.07.038_bib40","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib41","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4-and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/all.13775","article-title":"Bronchial asthma triggered by house dust mites in patients with local allergic rhinitis","volume":"74","author":"Campo","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.07.038_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib44","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/alr.22865","article-title":"Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease","volume":"11","author":"Yong","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2025.07.038_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaip.2023.09.019","article-title":"Should biologics be used before aspirin desensitization in aspirin-exacerbated respiratory disease?","volume":"12","author":"Laidlaw","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.07.038_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.15586\/aei.v50i6.693","article-title":"A new classification option for NSAID hypersensitivity: Kalyoncu classification","volume":"50","author":"\u00d6zdemir","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaip.2025.07.038_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1034\/j.1398-9995.1999.00963.x","article-title":"Occurrence of allergic conditions in asthmatics with analgesic intolerance","volume":"54","author":"Kalyoncu","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.07.038_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-024-00653-6","article-title":"Safety of biological therapies for severe asthma: an analysis of suspected adverse reactions reported in the WHO Pharmacovigilance Database","volume":"38","author":"Cutroneo","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaip.2025.07.038_bib49","series-title":"An economic assessment of the FDA proposal rule: Medication guides: Patient medication information","author":"Pham","year":"2023"},{"key":"10.1016\/j.jaip.2025.07.038_bib50","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/jocd.14507","article-title":"Transient alopecia areata following treatment with omalizumab in a patient with asthma and nasal polyps: a potential dermatological adverse event","volume":"21","author":"Jin","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaip.2025.07.038_bib51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2340\/00015555-3244","article-title":"Alopecia areata after omalizumab treatment for chronic spontaneous urticaria","volume":"99","author":"Magen","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2025.07.038_bib52","first-page":"205","article-title":"Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?","volume":"48","author":"Konstantinou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.038_bib53","series-title":"The Essential Guide to Effect Sizes: Statistical Power, Meta-analysis, and the Interpretation of Research Results","author":"Ellis","year":"2010"},{"key":"10.1016\/j.jaip.2025.07.038_bib54","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.jaip.2025.07.038_bib55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size\u2014or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J Graduate Med Educ"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825007287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825007287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:26:16Z","timestamp":1777116376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825007287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2213219825007287"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.07.038","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}